TAKE Solutions Limited (TAKE.NS)
INR 8.67
(2.0%)
INR 8.67
(2.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -213.49 Million INR | 40.25% |
| 2022 | -357.29 Million INR | 45.47% |
| 2021 | -655.23 Million INR | 64.04% |
| 2020 | -1.82 Billion INR | -9202.3% |
| 2019 | 20.02 Million INR | -99.14% |
| 2018 | 2.31 Billion INR | 13.88% |
| 2017 | 2.03 Billion INR | 20.0% |
| 2016 | 1.69 Billion INR | 21.47% |
| 2015 | 1.39 Billion INR | 55.29% |
| 2014 | 898.12 Million INR | 27.62% |
| 2013 | 703.75 Million INR | -38.82% |
| 2012 | 1.15 Billion INR | -5.83% |
| 2011 | 1.22 Billion INR | 14.05% |
| 2010 | 1.07 Billion INR | 84.87% |
| 2009 | 579.38 Million INR | -22.82% |
| 2008 | 750.65 Million INR | -3.24% |
| 2007 | 775.75 Million INR | 67.88% |
| 2006 | 462.09 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q3 | -7.22 Million INR | -216.67% |
| 2023 Q4 | -167.89 Million INR | -2225.35% |
| 2023 FY | -213.49 Million INR | 40.25% |
| 2023 Q1 | -34.68 Million INR | -1290.12% |
| 2023 Q2 | -2.28 Million INR | 93.43% |
| 2022 Q4 | 2.91 Million INR | 104.67% |
| 2022 FY | -357.29 Million INR | 45.47% |
| 2022 Q2 | -277.01 Million INR | -214.69% |
| 2022 Q3 | -62.43 Million INR | 77.46% |
| 2022 Q1 | -88.02 Million INR | 75.58% |
| 2021 Q3 | -403.17 Million INR | -2061.44% |
| 2021 Q4 | -360.4 Million INR | 10.61% |
| 2021 FY | -655.23 Million INR | 64.04% |
| 2021 Q2 | -18.65 Million INR | -132.78% |
| 2021 Q1 | 56.9 Million INR | -89.64% |
| 2020 Q2 | -1.05 Billion INR | -38.42% |
| 2020 Q3 | -229.48 Million INR | 78.27% |
| 2020 Q4 | 549.31 Million INR | 339.36% |
| 2020 FY | -1.82 Billion INR | -9202.3% |
| 2020 Q1 | -762.82 Million INR | 57.55% |
| 2019 Q4 | -1.79 Billion INR | -367.17% |
| 2019 Q2 | 654.92 Million INR | 1.47% |
| 2019 Q1 | 645.44 Million INR | 10.41% |
| 2019 FY | 20.02 Million INR | -99.14% |
| 2019 Q3 | 672.56 Million INR | 2.69% |
| 2018 Q1 | 601.71 Million INR | 3.15% |
| 2018 Q3 | 467.04 Million INR | -29.44% |
| 2018 Q4 | 584.59 Million INR | 25.17% |
| 2018 FY | 2.31 Billion INR | 13.88% |
| 2018 Q2 | 661.89 Million INR | 10.0% |
| 2017 Q4 | 583.34 Million INR | 8.72% |
| 2017 FY | 2.03 Billion INR | 20.0% |
| 2017 Q3 | 536.56 Million INR | 14.92% |
| 2017 Q2 | 466.9 Million INR | 3.73% |
| 2017 Q1 | 450.12 Million INR | 7.26% |
| 2016 FY | 1.69 Billion INR | 21.47% |
| 2016 Q1 | 427.91 Million INR | -7.18% |
| 2016 Q2 | 466.65 Million INR | 9.05% |
| 2016 Q3 | 412.59 Million INR | -11.59% |
| 2016 Q4 | 419.65 Million INR | 1.71% |
| 2015 Q4 | 461.03 Million INR | 42.78% |
| 2015 FY | 1.39 Billion INR | 55.29% |
| 2015 Q3 | 322.89 Million INR | -1.06% |
| 2015 Q2 | 326.34 Million INR | -30.95% |
| 2015 Q1 | 472.6 Million INR | 71.26% |
| 2014 Q2 | 182.52 Million INR | -0.47% |
| 2014 Q1 | 183.37 Million INR | 43.51% |
| 2014 FY | 898.12 Million INR | 27.62% |
| 2014 Q4 | 275.96 Million INR | 16.05% |
| 2014 Q3 | 237.8 Million INR | 30.29% |
| 2013 Q1 | 190.35 Million INR | 15.66% |
| 2013 Q2 | 212.58 Million INR | 11.68% |
| 2013 Q3 | 202.37 Million INR | -4.8% |
| 2013 FY | 703.75 Million INR | -38.82% |
| 2013 Q4 | 127.78 Million INR | -36.86% |
| 2012 Q1 | 395.98 Million INR | 64.9% |
| 2012 Q2 | 320.38 Million INR | -19.09% |
| 2012 FY | 1.15 Billion INR | -5.83% |
| 2012 Q4 | 164.58 Million INR | -38.9% |
| 2012 Q3 | 269.37 Million INR | -15.92% |
| 2011 Q3 | 349.65 Million INR | 8.06% |
| 2011 FY | 1.22 Billion INR | 14.05% |
| 2011 Q2 | 323.57 Million INR | 0.0% |
| 2011 Q4 | 240.12 Million INR | -31.32% |
| 2010 FY | 1.07 Billion INR | 84.87% |
| 2009 FY | 579.38 Million INR | -22.82% |
| 2008 FY | 750.65 Million INR | -3.24% |
| 2007 FY | 775.75 Million INR | 67.88% |
| 2006 FY | 462.09 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Biocon Limited | 50.83 Billion INR | 100.42% |
| Blue Jet Healthcare Limited | 3.37 Billion INR | 106.331% |
| Concord Biotech Limited | 6.26 Billion INR | 103.409% |
| Dishman Carbogen Amcis Limited | -413 Million INR | 48.308% |
| Jubilant Ingrevia Limited | 2.93 Billion INR | 107.262% |
| Lyka Labs Limited | 29.13 Million INR | 832.887% |
| Panacea Biotec Limited | - INR | Infinity% |
| Piramal Pharma Limited | 4.31 Billion INR | 104.948% |
| SMS Lifesciences India Limited | 359.47 Million INR | 159.39% |
| Supriya Lifescience Limited | 1.57 Billion INR | 113.584% |
| Syngene International Limited | 6.46 Billion INR | 103.301% |
| Zota Health Care Limited | -129.79 Million INR | -64.481% |